Full Press Release Details
Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies
to support accelerated commercialization of Koligo's KYSLECEL ,
a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis
to rapidly advance KT-PC-301, an autologous cell therapy under investigation
for the treatment of COVID-19-related Acute Respiratory Disease Syndrome ("ARDS")
to leverage Koligo's 3D-V bioprinting technology across its POCare Platform
MD - September 29, 2020 - Orgenesis Inc. (NASDAQ: ORGS) ("Orgenesis" or the "Company"),
a global biotech company working to unlock the full potential of cell and gene therapies, and Koligo Therapeutics, Inc. ("Koligo"),
a regenerative medicine company, today announced that the two companies have entered into a definitive merger agreement, subject
to final closing conditions, with expected completion before year-end ("Transaction").
is a leader in developing personalized cell therapies utilizing the patient's own (autologous) cells. Koligo has successfully
launched its first commercial product, KYSLECEL, and plans to commence a phase 2 trial of KT-PC-301 for COVID-19-related ARDS.
Koligo's development stage technology utilizes 3D bioprinting and vascularization with autologous cells ("3D-V"
technology) to create biodegradable and shelf-stable three-dimensional cell and tissue implants. The 3D-V technology is being
developed for diabetes and pancreatitis, with longer term applications for neural, liver, and other cell/tissue transplants.
closing of the Transaction, Orgenesis plans to accelerate the commercial scaleup of KYSLECEL throughout the United States and,
subject to regulatory and logistical considerations, in international markets as well. After closing of the Transaction, and subject
to FDA review and clearance of the Company's Investigational New Drug application, Orgenesis expects to start patient recruitment
for a phase 2 randomized clinical trial of KT-PC-301 in COVID-19 patients. Orgenesis also plans to leverage Koligo's 3D-V
bioprinting technology across its POCare platform.
the terms of the merger agreement, Orgenesis will acquire all of the outstanding stock of Koligo from its shareholders (the founders
and staff of Koligo and a subsidiary of Bergen Special Opportunity Fund, LP, an institutional investor managed by Bergen Asset
Management, LLC). The agreed consideration terms are an aggregate of $15 million in shares of Orgenesis' common stock valued
at $7.00 per share which shall be issued to Koligo's accredited investors (with certain non-accredited investors to be paid
solely in cash) and an assumption of $1.3 million in Koligo's liabilities, estimated to be substantially all of Koligo's
liabilities. Additional details of the Transaction will be available in the Company's Form 8-K, which will be filed with
the Securities and Exchange Commission, and will be available at www.sec.gov.
KYSLECEL is commercially available in the United States for chronic and recurrent acute pancreatitis in a surgical procedure commonly
called Total Pancreatectomy with Islet Autologous-Transplant ("TPIAT"). TPIAT has been proven to provide significant
pain relief, improved quality of life, and a reduction in the need for pain medication for patients suffering from chronic or
recurrent acute pancreatitis. KYSLECEL infusion after a total pancreatectomy helps preserve insulin secretory capacity and reduce
the risk of diabetic complications. KYSLECEL is made from a patient's own pancreatic islets - the cells that make
insulin to regulate blood sugar.
has commenced its commercial pilot program for KYSLECEL at six U.S. hospitals, treating 40 patients to date. The KYSLECEL pilot
program has generated approximately $2 million in sales revenue. KYSLECEL has also been shown to result in significant savings
to payors over traditional chronic pancreatitis management. Following the closing of the Transaction, Orgenesis plans to make
KYSLECEL available to an increasing number of hospitals throughout the United States through its POCare Network.
lead clinical development program is for KT-PC-301, an autologous cell therapy under investigation for the treatment of COVID-19-related
Acute Respiratory Disease Syndrome (ARDS). KT-PC-301 is comprised of autologous stromal and vascular fraction cells ("SVF")
derived from each patient's adipose (fat) tissue. KT-PC-301 contains a population of mesenchymal stem cells, vascular endothelial
cells, and immune cells which migrate to the patient's lungs and other peripheral sites of inflammation. Nonclinical and
clinical evidence demonstrate that KT-PC-301 may: (1) stabilize microcirculation to improve oxygenation; (2) maintain T and B
lymphocytes to support antibody production; and (3) induce an anti-inflammatory effect.
has completed a pre-IND (Investigational New Drug) consultation with the U.S. Food and Drug Administration to start clinical trials
of KT-PC-301 in COVID-19-related ARDS. Following the closing of the Transaction, and subject to FDA review and clearance of the
Company's Investigational New Drug application, Orgenesis expects to start patient recruitment for a phase 2 randomized
clinical trial of KT-PC-301 in COVID-19 patients. As currently planned, the phase 2 trial is expected to enroll 75 patients and
evaluate the safety and efficacy of KT-PC-301. Mohamed Saad, MD, Chief of Division of Pulmonary, Critical Care, and Sleep Disorders
Medicine at the University of Louisville, will be the lead clinical investigator on the trial.
3D-V bioprinting technology is designed to support development of a number of product candidates for the treatment of diabetes,
cancer, neurodegenerative disease, and other serious diseases. The 3D-V technology platform is able to print three-dimensional
cell and tissue constructs with a vascular network. Key benefits of the 3D-V approach include: faster revascularization/inosculation
of cell/tissue transplant to improve engraftment; host tolerance of the graft while minimizing need for immune suppressive drugs;
better site of transplant administration of such products; and scaffolding to keep cell/tissue in place in vivo. These solutions
are ideally suited for islet transplant and other cell/tissue transplant applications.
the closing of the Transaction, Koligo's management team will be joining Orgenesis to continue commercial and development
activities. Koligo's CEO, Matthew Lehman, is an accomplished executive in the biotech and regenerative medicine fields.
Prior to co-founding Koligo, he was CEO of Prima Biomed Ltd (now Immutep Ltd, a Nasdaq (IMMP) and ASX (IMM) listed biotech company).
Stuart Williams, PhD, Chief Technology Officer, is a bioengineer and thought leader in regenerative medicine, with over 300 publications
and 20 issued patents in the field. Dr. Williams has co-founded three other biotech companies and is an experienced academic-industry
collaborator. Michael Hughes, MD, Chief Medical Officer, is a transplant surgeon who started the islet transplant program at University
of Louisville which was the genesis of Koligo's KYSLECEL program. He has successfully treated nearly 50 chronic pancreatitis
patients with islet autologous transplant after pancreatectomy. Balamurugan Appakalai, PhD, has more than 20 years of islet isolation
experience, having processed more than 800 human pancreases. He is a leader in the field of islet transplant with 100+ publications.
Caplan, Chief Executive Officer of Orgenesis, stated, "We are pleased to announce this transformative acquisition, which
we expect will add broad capabilities to our therapeutic and technology platform, and will further our leadership in the cell
and gene therapy field. Based on several phase 1 studies, Koligo's KT-PC-301, using a patient's own cells, has demonstrated
safety and tolerability, and has shown signs of efficacy to support continued development in COVID-19-related ARDS. If successful
for the treatment of COVID-19-related ARDS, KT-PC-301 is likely to have applications in other acute and chronic respiratory indications,
areas that represent significant unmet medical need. In addition, we see significant potential in KYSLECEL, a commercial stage
asset for the treatment of chronic and acute recurrent pancreatitis, which we plan to introduce through our global network of
hospitals. Finally, Koligo's 3D-V bioprinting technology is highly complementary to our POCare Platform, as we implement
new technologies to improve efficacy and lower the costs of cell and gene therapies. I would like to personally welcome Matthew
and the rest of the Koligo team to the Orgenesis organization when the Transaction closes. We believe that their skills and experience
will be an important addition as we execute on our strategy to unlock the power of cell and gene therapies and make them accessible
Lehman, Chief Executive Officer of Koligo Therapeutics, stated, "The merger with Orgenesis marks a major milestone for our
company and builds on our recent progress, including the Pre-IND package submitted to the U.S. FDA for KT-PC-301 and our pilot
commercial program for KYSLECEL. The Orgenesis team brings extensive clinical, regulatory, and manufacturing expertise well suited
to supporting Koligo's goals. Orgenesis' intellectual property is highly complementary to Koligo's technology
and the combined companies will work to advance a robust commercial and development product portfolio. Orgenesis' POCare
technologies are also ideally suited for low-cost and efficient production of autologous cell therapies at the point of care,
which we believe will considerably enhance the delivery of these therapies to patients. Additionally, we believe Orgenesis'
global network of leading hospitals and healthcare institutions will enable us to accelerate the commercial rollout of KYSLECEL.
We are quite encouraged by the outlook for the business and look forward to leveraging Orgenesis' POCare Platform in order
to accelerate the timeline to bringing our innovative cell therapies to market. Through this merger, we believe we can maximize
value for all shareholders and we are grateful to Orgenesis for this opportunity."
Cohen Zedek Latzer Baratz LLP and KPMG advised Orgenesis on the Transaction. Maxim Group LLC acted as a finder and Nelson Mullins
Riley & Scarborough, LLP advised Koligo on the Transaction.
Therapeutics, Inc. is a US regenerative medicine company. Koligo's first commercial product is KYSLECEL
(autologous pancreatic islets) for chronic and acute recurrent pancreatitis. Koligo's 3D-V technology platform incorporates
the use of advanced 3D bioprinting techniques and vascular endothelial cells to support development of transformational cell and
tissue products for serious diseases. More information is available at www.koligo.net.
is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible
format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare
Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative
POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally
harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable,
and decentralized production. The Network brings together patients, doctors, industry partners, research institutes and hospitals
worldwide to achieve harmonized, regulated clinical development and production of the therapies. Learn more about the work Orgenesis
is doing at www.orgenesis.com.